Indication
Enflonsia is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Enflonsia should be used in accordance with official recommendations.
Loading your page…
Respiratory Syncytial Virus Vaccines
Marketing Authorisation Holder: Merck Sharp Dohme Limited
EMA Authorisation: 15/04/2026
INN: clesrovimab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Enflonsia: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.